Qelbree (Viloxazine HCl) Patent Expiration, LOE Window & CMS Spending

Qelbree (Viloxazine HCl) by Supernus: FDA Orange Book LOE 2035-04-02, 0 AB generics, $187.2M 2024 CMS Part D & Medicaid spend, and 11 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorSupernus
FDA Application & PathwayN211964 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2035-04-02
Orange Book Patents (*PED Extensions)6 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$187.2M
2024 Medicare Part D Spend$6.8M
2024 Medicaid Spend$180.4M
Reported Wholesale Price Change (CA SB 17)11 WAC filings (max 19.1% 2-yr change)